Tilray sinks as Schedule III headline turns into a “sell-the-news” reversal and dilution worries resurface

Tilray Brands, Inc. (TLRY) is down 9.5% today. Here is some analysis on what might have caused this price movement.

Analysis: TLRY appeared to fade after an early surge tied to a federal move to shift certain medical cannabis activity to Schedule III, with traders taking profits once the headline hit. The selloff also fits with an ongoing dilution overhang after the company filed for a sizable at-the-market equity program earlier in April.

Details:

A U.S. federal order signed April 23, 2026 reclassified state-licensed medical marijuana as Schedule III, a change that can improve after-tax economics for qualifying operators but does not broadly legalize cannabis at the federal level.

TLRY’s tape showed a sharp intraday reversal (opening strong and then sliding), a pattern consistent with “buy the rumor, sell the news” trading after a high-volatility catalyst.

An SEC prospectus supplement filed April 15, 2026 outlines an at-the-market offering program for up to $180 million of common stock, which can pressure shares due to potential dilution.

Earlier this month, Tilray reported Q3 fiscal 2026 results with net revenue of $206.7 million and a net loss, keeping investor focus on funding needs and profitability rather than headlines alone.

Sources:

Associated Press, SEC, Tilray Brands Investor Relations

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$TLRY Insider Trading Activity

$TLRY insiders have traded $TLRY stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $TLRY stock by insiders over the last 6 months:

DAVID G. HOPKINSON sold 33,556 shares for an estimated $232,878

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$TLRY Hedge Fund Activity

We have seen 61 institutional investors add shares of $TLRY stock to their portfolio, and 272 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

TIDAL INVESTMENTS LLC removed 2,613,053 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $23,595,868
HRT FINANCIAL LP removed 1,484,926 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $13,408,881
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 1,012,613 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $9,143,895
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 692,656 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $6,254,683
HILLSDALE INVESTMENT MANAGEMENT INC. added 536,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,840,080
UBS GROUP AG added 500,949 shares (+180.4%) to their portfolio in Q4 2025, for an estimated $4,523,569
JANE STREET GROUP, LLC removed 441,350 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,985,390

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$TLRY Price Targets

Multiple analysts have issued price targets for $TLRY recently. We have seen 2 analysts offer price targets for $TLRY in the last 6 months, with a median target of $8.5.

Here are some recent targets:

Bill Kirk from Roth Capital set a target price of $10.0 on 04/02/2026
Robert Moskow from TD Cowen set a target price of $7.0 on 03/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.